LPS derived from Escherichia coli serotype 055:B5 ( Sigma-Aldrich, USA, catalog: L2880, 5 mg kg−1) was dissolved in 0.9% saline (0.3 ml) and injected intraperitoneally to mice for induction of SAE model [17 (link)]. Control animals were injected with equivalent volumes of saline. The animals were randomly divided into control group and LPS group. The time that mice received intraperitoneal injection of LPS as well as killed are between 9 and 11 a.m.
FTY720 (Melonepharma, China, catalog: 162359-56-0) were used for eliminating peripheral blood lymphocytes and therefore reducing meningeal infiltration of lymphocytes as reported before [10 (link)]. Briefly, animals were treated daily with an oral administration (1 mg kg−1 in 0.1 ml saline by gavage) of FTY720 starting at 1 week before LPS injection for 7 days and followed with treatment throughout the fear conditioning test. The proper time and dosage of FTY720 used was based on a previous study by Kipnis et al. [10 (link)]. Mice subjected to intragastric administration of equal saline with same protocol were used for control.
For investigating the role of monoclonal anti-proBDNF antibody (McAb-proB), mice were treated with intraperitoneal injection of 100 μg in 0.3 ml McAb-proB at 30 min before the induction of SAE model, or bilateral intracerebroventricular delivery (i.c.v) of 1 μg in 1 μl McAb-proB 3 days before LPS injection. The biological activity and safety of McAb-proB have been characterized by our previous studies [15 (link), 16 (link), 18 (link), 19 (link)]. Mouse IgG (CMCTAG, catalog: AT1596) were used for isotype control of related experiments. The dosage of McAb-proB used for treatment is followed by our previous research [15 (link), 16 (link), 18 (link)].
FTY720 (Melonepharma, China, catalog: 162359-56-0) were used for eliminating peripheral blood lymphocytes and therefore reducing meningeal infiltration of lymphocytes as reported before [10 (link)]. Briefly, animals were treated daily with an oral administration (1 mg kg−1 in 0.1 ml saline by gavage) of FTY720 starting at 1 week before LPS injection for 7 days and followed with treatment throughout the fear conditioning test. The proper time and dosage of FTY720 used was based on a previous study by Kipnis et al. [10 (link)]. Mice subjected to intragastric administration of equal saline with same protocol were used for control.
For investigating the role of monoclonal anti-proBDNF antibody (McAb-proB), mice were treated with intraperitoneal injection of 100 μg in 0.3 ml McAb-proB at 30 min before the induction of SAE model, or bilateral intracerebroventricular delivery (i.c.v) of 1 μg in 1 μl McAb-proB 3 days before LPS injection. The biological activity and safety of McAb-proB have been characterized by our previous studies [15 (link), 16 (link), 18 (link), 19 (link)]. Mouse IgG (CMCTAG, catalog: AT1596) were used for isotype control of related experiments. The dosage of McAb-proB used for treatment is followed by our previous research [15 (link), 16 (link), 18 (link)].
Free full text: Click here
